Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Published byIvan Kusuma Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to."— Presentation transcript:

1 Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy.
VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. Tumor growth and survival of three different melanoma models treated with control (Iso) or αR3-blocking antibodies receiving different immunotherapies (arrows indicate times of administration). (A and B) B16-OVA/VC tumors treated with ATT in (A) WT (n ≥ 15) and (B) K14-VEGFR-3-Ig mice that lack dermal lymphatics (n = 4). ns, not significant. (C to F) B16-OVA/VC tumors in WT mice treated with (C) ex vivo activated DCs (DC vax; n = 6), (D) 50 μg of CpG (n = 6), (E) 10 μg of OVA + 50 μg of CpG (n ≥ 8), and (F) 2 μg of Trp2 peptide–conjugated nanoparticles (NP-Trp2) + 50 μg of CpG (n = 7). (G) B16/VC tumors treated with NP-Trp μg of CpG (n = 6). (H) Tamoxifen-induced tumors in BrafV600E/Pten−/− mice treated with CpG + gp100 peptide (days 8 and 12) and anti–PD-1 antibody (day 12 and every 4 days thereafter). Each panel shows data from one (B to D, F, and G), two (E), or three (A) independent experiments. *P < 0.05, **P < 0.01, ***P < by two-tailed Student’s t test for growth curves and log-rank (Mantel-Cox) test for comparing survival curves. Manuel Fankhauser et al., Sci Transl Med 2017;9:eaal4712 Published by AAAS

Download ppt "Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to."

Similar presentations

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.
Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.
Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.

Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
In vivo responses of AMLMLL to ATRi.

In vivo responses of AMLMLL to ATRi.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
MRSA virulence proteins cause LMC death and diminished CLV function

MRSA virulence proteins cause LMC death and diminished CLV function
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.

Similar presentations

Ads by Google